KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Net Income: 2009-2024

Historic Net Income for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $4.4 billion.

  • Regeneron Pharmaceuticals' Net Income rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Net Income stood at $4.4 billion for FY2024, which was up 11.61% from $4.0 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Net Income's 5-year high stood at $8.1 billion during FY2021, with a 5-year trough of $3.5 billion in FY2020.
  • Moreover, its 3-year median value for Net Income was $4.3 billion (2022), whereas its average is $4.2 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Net Income skyrocketed by 129.86% in 2021, and later tumbled by 46.28% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Net Income (Yearly) stood at $3.5 billion in 2020, then soared by 129.86% to $8.1 billion in 2021, then crashed by 46.28% to $4.3 billion in 2022, then fell by 8.87% to $4.0 billion in 2023, then grew by 11.61% to $4.4 billion in 2024.